MX2023001444A - Derivados de pirazolo[1,5-a]pirimidina sustituidos con heterociclicos farmacologicamente activos. - Google Patents
Derivados de pirazolo[1,5-a]pirimidina sustituidos con heterociclicos farmacologicamente activos.Info
- Publication number
- MX2023001444A MX2023001444A MX2023001444A MX2023001444A MX2023001444A MX 2023001444 A MX2023001444 A MX 2023001444A MX 2023001444 A MX2023001444 A MX 2023001444A MX 2023001444 A MX2023001444 A MX 2023001444A MX 2023001444 A MX2023001444 A MX 2023001444A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- pyrimidine derivatives
- relates
- pharmacologically active
- substituted pyrazolo
- Prior art date
Links
- LDIJKUBTLZTFRG-UHFFFAOYSA-N pyrazolo[1,5-a]pyrimidine Chemical class N1=CC=CN2N=CC=C21 LDIJKUBTLZTFRG-UHFFFAOYSA-N 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 230000003281 allosteric effect Effects 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La invención se refiere a nuevos derivados de pirazolo[1,5-a]pirimidina de fórmula (I) o sales farmacéuticamente aceptables, metabolitos biológicamente activos, profármacos, racematos, enantiómeros, diastereómeros, solvatos e hidratos de estos que sirven como moduladores alostéricos positivos del receptor GABAB. La invención también se refiere al proceso para producir dichos compuestos y los intermedios clave utilizados en el proceso. La invención se refiere además a las composiciones farmacéuticas que comprenden dichos compuestos opcionalmente en combinación con dos o más agentes terapéuticos diferentes y al uso de dichos compuestos en métodos para tratar enfermedades y afecciones mediadas y moduladas por el mecanismo alostérico positivo del receptor GABAB. La invención también proporciona un método para la fabricación de medicamentos útiles en el tratamiento de dichos trastornos. (ver Fórmula).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HUP2000254 | 2020-08-05 | ||
| PCT/IB2021/057180 WO2022029666A1 (en) | 2020-08-05 | 2021-08-05 | PHARMACOLOGICALLY ACTIVE HETEROCYCLIC-SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023001444A true MX2023001444A (es) | 2023-03-08 |
Family
ID=89662993
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023001444A MX2023001444A (es) | 2020-08-05 | 2021-08-05 | Derivados de pirazolo[1,5-a]pirimidina sustituidos con heterociclicos farmacologicamente activos. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20230286988A1 (es) |
| EP (1) | EP4192833A1 (es) |
| JP (1) | JP2023536197A (es) |
| KR (1) | KR20230049677A (es) |
| CN (1) | CN116075514A (es) |
| AR (1) | AR123154A1 (es) |
| AU (1) | AU2021319420A1 (es) |
| BR (1) | BR112023001060A2 (es) |
| CA (1) | CA3185566A1 (es) |
| CL (1) | CL2023000352A1 (es) |
| CO (1) | CO2023001367A2 (es) |
| IL (1) | IL300208A (es) |
| MX (1) | MX2023001444A (es) |
| PE (1) | PE20240107A1 (es) |
| TW (1) | TW202220992A (es) |
| WO (1) | WO2022029666A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116077459B (zh) * | 2023-04-10 | 2023-07-07 | 上海赛默罗生物科技有限公司 | α5-GABAA受体调节剂的胶囊剂及其制备方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL348294A1 (en) | 1998-12-18 | 2002-05-20 | Schering Corp | Farnesyl protein transferase inhibitors |
| PL1725239T3 (pl) | 2004-03-02 | 2007-12-31 | Hoffmann La Roche | Pochodne 4-(sulfanylopirymidyn-4-ylometylo)morfoliny i związki pokrewne jako ligandy receptorów GABA do leczenia lęku, depresji i padaczki |
| GB0512844D0 (en) | 2005-06-23 | 2005-08-03 | Novartis Ag | Organic compounds |
| WO2008024371A2 (en) | 2006-08-21 | 2008-02-28 | Prexa Pharmaceuticals, Inc. | Multimediator transporter inhibitors for use in treatment of central nervous system disorders |
| CA2771568A1 (en) | 2009-09-04 | 2011-03-10 | Novartis Ag | Heteroaryl compounds as kinase inhibitors |
| TWI648281B (zh) | 2013-10-17 | 2019-01-21 | 日商安斯泰來製藥股份有限公司 | 含硫二環式化合物 |
| HRP20212035T1 (hr) | 2014-04-23 | 2022-04-01 | Dart Neuroscience Llc | Pripravci koji sadrže supstituirane [1,2,4]triazolo[1,5-a]pirimidin-7-il spojeve kao inhibitore pde2 |
| LT3149001T (lt) * | 2014-05-28 | 2019-08-12 | Novartis Ag | Naujieji pirazolo pirimidino dariniai ir jų panaudojimas kaip malt1 inhibitorių |
| WO2016169995A1 (en) | 2015-04-20 | 2016-10-27 | AbbVie Deutschland GmbH & Co. KG | Substituted pyrazolopyrimidines and method of use |
| JP2018199623A (ja) * | 2015-10-22 | 2018-12-20 | 大正製薬株式会社 | 含窒素縮合複素環化合物 |
| HU231150B1 (hu) | 2017-03-13 | 2021-03-29 | Richter Gedeon Nyrt | Eljárás racém 3-alkilpiperidin-3-karbonsav-etil-észterek optikai izomerjeinek elválasztására |
| HU231058B1 (hu) | 2017-03-13 | 2020-04-28 | Richter Gedeon Nyrt. | Gyógyászatilag hatékony aliciklusos-szubsztituált pirazolo[1,5-a]pirimidin származékok |
| HU231057B1 (hu) * | 2017-03-13 | 2020-04-28 | Richter Gedeon Nyrt | Gyógyászatilag hatékony aril-szubsztituált pirazolo[1,5-a]pirimidin származékok |
-
2021
- 2021-08-02 TW TW110128314A patent/TW202220992A/zh unknown
- 2021-08-05 BR BR112023001060A patent/BR112023001060A2/pt unknown
- 2021-08-05 WO PCT/IB2021/057180 patent/WO2022029666A1/en active Application Filing
- 2021-08-05 IL IL300208A patent/IL300208A/en unknown
- 2021-08-05 CA CA3185566A patent/CA3185566A1/en active Pending
- 2021-08-05 AR ARP210102183A patent/AR123154A1/es unknown
- 2021-08-05 JP JP2023507435A patent/JP2023536197A/ja active Pending
- 2021-08-05 KR KR1020237007966A patent/KR20230049677A/ko active Search and Examination
- 2021-08-05 US US18/040,456 patent/US20230286988A1/en active Pending
- 2021-08-05 EP EP21755582.0A patent/EP4192833A1/en active Pending
- 2021-08-05 MX MX2023001444A patent/MX2023001444A/es unknown
- 2021-08-05 PE PE2023000205A patent/PE20240107A1/es unknown
- 2021-08-05 CN CN202180058179.4A patent/CN116075514A/zh active Pending
- 2021-08-05 AU AU2021319420A patent/AU2021319420A1/en active Pending
-
2023
- 2023-02-03 CL CL2023000352A patent/CL2023000352A1/es unknown
- 2023-02-08 CO CONC2023/0001367A patent/CO2023001367A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4192833A1 (en) | 2023-06-14 |
| AU2021319420A1 (en) | 2023-03-16 |
| PE20240107A1 (es) | 2024-01-22 |
| TW202220992A (zh) | 2022-06-01 |
| CA3185566A1 (en) | 2022-02-10 |
| AR123154A1 (es) | 2022-11-02 |
| JP2023536197A (ja) | 2023-08-23 |
| US20230286988A1 (en) | 2023-09-14 |
| IL300208A (en) | 2023-03-01 |
| CO2023001367A2 (es) | 2023-02-16 |
| AU2021319420A8 (en) | 2023-03-30 |
| CN116075514A (zh) | 2023-05-05 |
| BR112023001060A2 (pt) | 2023-03-07 |
| WO2022029666A1 (en) | 2022-02-10 |
| KR20230049677A (ko) | 2023-04-13 |
| CL2023000352A1 (es) | 2023-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019501968A1 (en) | PHARMACOLOGICALLY ACTIVE ALICYCLIC-SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES | |
| AU5141293A (en) | Substituted quinuclidines as substance p antagonists | |
| MX2022015856A (es) | Compuestos de dihidroquinolin sulfonamida de ciclobutilo. | |
| MX2022015622A (es) | Compuestos de dihidroquinolin sulfonamida de ciclopropilo. | |
| EP3891157A1 (en) | 4-amino or 4-alkoxy-substituted aryl sulfonamide compounds with selective activity in voltage-gated sodium channels | |
| ATE402707T1 (de) | Imidazoä1,5aütriazoloä1,5dübenzodiazepin- derivative zur behandlung kognitiver störungen | |
| US20210332058A1 (en) | Compounds, Compositions and Methods | |
| CA3131312A1 (en) | Treatment with p2x3 modulators | |
| MX2023001444A (es) | Derivados de pirazolo[1,5-a]pirimidina sustituidos con heterociclicos farmacologicamente activos. | |
| US7723324B2 (en) | Imidazo[1,2-A]pyridine anxiolytics | |
| MX2024003459A (es) | Metodos de tratamiento de trastornos metabolicos. | |
| MX2023009285A (es) | Compuestos novedosos. | |
| MX2022011354A (es) | Compuestos de pirimidina fusionados como moduladores de kcc2. | |
| JP2016536320A (ja) | 神経変性疾患の処置用の神経新生薬としてのピリド［４，３−ｂ］ピラジン−２−カルボキサミド | |
| GB2583606A (en) | Indoleamine 2,3-Dioxygenase inhibitors and use of same in medicine | |
| CN112010818A (zh) | 吗啉酰胺衍生物及其用途 | |
| CN111072604A (zh) | α-氨基酰胺衍生物及其用途 | |
| MX2023004297A (es) | Derivados de 2-oxo-dihidroquinolin-3-carboxamida como moduladores del receptor gaba tipo a. | |
| MX2023011376A (es) | Nuevos moduladores alostericos negativos de ciclopenta[c]pirrol de nr2b. | |
| RU2554344C2 (ru) | Производные тетрагидропирана против неврологических заболеваний | |
| MX2023013400A (es) | Derivados heterociclicos fusionados como moduladores alostericos negativos del receptor mglu7. | |
| MX2024003812A (es) | Derivados de amina bicíclicos como moduladores de receptor gabaa a5. |